The Affordable Premiums for Seniors Act of 2026 extends a Medicare Part D premium stabilization program through 2029 and makes it permanent starting in 2030, provided that ending the program would not cause prescription drug premiums to rise. This legislation directly affects seniors enrolled in Medicare prescription drug plans by aiming to keep their costs stable over time. The bill requires the Secretary of Health and Human Services to issue updated operational guidelines for the program within 30 days of enactment.
The Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 requires Medicare Part D and Advantage plans to use a standardized public bidding process for pharmacy benefit managers starting in 2028, ensuring that the lowest projected net effective cost is generally selected. The bill mandates that plan sponsors maintain real-time tools to track actual drug costs and escrow funds to refund enrollees if they are overcharged relative to their bids. It also establishes a new five-star rating system for these plans based on how closely actual spending matches projections, with low-performing plans required to notify beneficiaries of alternative options. Additionally, the legislation extends similar transparency requirements to commercial health plans by requiring them to disclose projected net effective costs in their bid submissions.
This House resolution supports designating September 20, 2026, as "Pharmacy Workforce Suicide Awareness Day" to highlight mental health challenges among pharmacists and pharmacy technicians. The bill cites high rates of burnout, stress, and suicide risk within the profession as reasons for the designation. It encourages the President to issue a proclamation calling for national awareness activities and honors those who have died by suicide. Additionally, the resolution recognizes the need for further research into barriers to mental health treatment and strategies to prevent suicide in this workforce.
This resolution expresses the House of Representatives' view that Federally Qualified Health Centers should maintain a single, unified definition for all patients rather than adopting separate definitions for different types of medical services. The bill argues that this consistent approach is essential to keep administrative costs low and ensure that approximately 32 million underserved Americans have access to comprehensive care, including prescription drugs purchased through the 340B Drug Pricing Program. By opposing service-specific patient definitions, the resolution aims to prevent restrictions that could force health centers to deny patients access to the full range of available health care services.
The INSULIN Act of 2026 mandates that group and individual health insurance plans cap out-of-pocket costs for selected insulin products at $35 per 30-day supply, effective for plan years beginning on or after January 1, 2028. This cost limit applies to a variety of insulin types and delivery devices, with the cap set at the lesser of $35 or 25 percent of the negotiated price net of concessions. The bill also prohibits insurers from imposing deductibles or prior authorization requirements for these covered products unless clinically justified for safety reasons.
Additionally, the legislation directs the Department of Health and Human Services to fund a resource center and hotline to help uninsured individuals find affordable insulin assistance programs, while requiring the Government Accountability Office to study the demographics of uninsured insulin users. Finally, it creates an expedited review process for biosimilar insulin applications when the Secretary determines there is inadequate competition in the market.
The SUSTAIN 340B Act overhauls the federal drug discount program to tighten oversight and prevent fraud by requiring covered entities to register their contract pharmacies and child sites with the Department of Health and Human Services. It establishes a new independent data clearinghouse to track claims and stop duplicate discounts, while also mandating that health insurers and pharmacy benefit managers treat 340B providers on equal footing without imposing discriminatory reimbursement terms. The bill defines strict criteria for what constitutes a valid patient relationship and authorizes a user fee program starting in fiscal year 2031 to fund additional audits and enforcement activities. These provisions directly affect safety-net healthcare providers, drug manufacturers, and insurance companies by increasing transparency requirements and expanding the government's authority to penalize non-compliance.
This bill amends Medicare to cover dental and oral health services for the first time, affecting all current and future Medicare beneficiaries. It defines covered services to include routine cleanings, fillings, extractions, root canals, crowns, dentures, and emergency care. For most individuals, federal payment for these services will gradually increase from 0% to 80% over an eight-year period, while low-income individuals eligible for prescription drug subsidies will receive 80% coverage immediately. The legislation also establishes frequency limits, such as two cleanings and exams per year and a five-year limit on full dentures, and requires the U.S. Preventive Services Task Force to include at least one oral health professional.
The Fair Prescription Pricing Act of 2026 would cap the out-of-pocket costs that individuals pay for prescription drugs by limiting deductibles, copayments, and coinsurance to no more than the nationwide average consumer price for that specific medication. This provision applies to both group health plans and individual health insurance policies, ensuring that patients using in-network pharmacies do not face charges higher than the standard market rate. The bill requires pharmacy benefit managers to adhere to these same cost-sharing limits as the insurance providers themselves. These restrictions would be implemented across federal laws governing public health services, employee retirement income security, and internal revenue codes to ensure consistent enforcement for plan years beginning after the act's enactment.
The Part D Premium Protection Act of 2026 would establish a temporary premium credit for Medicare Part D prescription drug plan enrollees in 2027. This credit is designed to match the average premium reduction observed during the Part D Premium Stabilization Demonstration program between January 1, 2025, and the end of 2026. Under the bill's provisions, insurance sponsors would charge enrollees their standard premiums minus this specific credit amount, with the floor set at zero dollars. The Secretary of Health and Human Services would then reimburse the sponsors for the difference between the charged premium and the full applicable rate.
This Senate resolution designates the first week of August 2026 as "National Community Health Center Week" to recognize the role these facilities play in providing affordable primary care across the United States. The bill highlights that community health centers serve a diverse range of populations, including those in rural and urban areas, by offering integrated services such as mental health, dental, and pharmacy care. It encourages the general public to participate in the observance by visiting local centers and celebrating the partnership between these organizations and their communities.
